Form 4: Akero Therapeutics CEO Gifts 74,538 Shares

Akero Therapeutics President and CEO, Andrew Cheng, donated 74,538 shares of common stock to a donor advised fund.

Summary

• Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (AKRO), reported a disposition of common stock.
• The transaction involved 74,538 shares of common stock, which were donated as a gift to a donor advised fund.
• The transaction date was November 20, 2025, and the shares were disposed of at a price of $0 per share.
• Following this transaction, Andrew Cheng beneficially owns 436,837 shares of Akero Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider disposition of shares as a gift, which is a neutral event for the company's operational performance and strategic direction. It reflects personal financial planning rather than a change in company fundamentals.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of common stock by a key executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing details a routine insider transaction, specifically a charitable gift of shares by a company executive, which is a common practice for personal financial and tax planning and does not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, which is generally not a significant concern unless it signals a broader trend of insider selling.
• Charitable Organizations: The donation benefits a donor advised fund, supporting philanthropic activities.

Key Dates

Keywords

Akero Therapeutics, AKRO, Andrew Cheng, Insider Transaction, Form 4, Stock Gift, CEO, Director, Common Stock